VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Automatic Data Processing, Inc. vs Amgen Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Automatic Data Processing, Inc.
ADP · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Automatic Data Processing, Inc.'s moat claims, evidence, and risks.
View ADP analysisAmgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Automatic Data Processing, Inc. leads (71 / 100 vs 70 / 100 for Amgen Inc.).
- Segment focus: Automatic Data Processing, Inc. has 2 segments (67.5% in Employer Services); Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Automatic Data Processing, Inc. has 7 moat types across 4 domains; Amgen Inc. has 5 across 3.
Primary market context
Automatic Data Processing, Inc.
Employer Services
Payroll processing and cloud HCM (HR, time, talent, tax, benefits) software and outsourcing
Global
Businesses (SMB to large enterprise)
SaaS and managed services provider
67.5%
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Side-by-side metrics
Moat coverage
Shared moat types
Automatic Data Processing, Inc. strengths
Amgen Inc. strengths
Segment mix
Automatic Data Processing, Inc. segments
Full profile >Employer Services
Oligopoly
Professional Employer Organization (PEO) Services
Competitive
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.